^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF L485W

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors (clinicaltrials.gov)
    P1/2, N=37, Terminated, Haihe Biopharma Co., Ltd. | N=150 --> 37 | Trial completion date: Dec 2024 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Mar 2023; Sponsor business decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation • NRAS mutation • BRAF V600 • ER mutation • NRAS Q61 • NRAS G13 • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF L597
    |
    HH2710
    1year
    A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    over1year
    A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=38 --> 17
    Enrollment closed • Enrollment change • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    almost2years
    A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC). (ASCO 2022)
    The primary endpoint of Part B is PFS, and secondary endpoints include OS, ORR, and DOR. This study has enrolled 43 patients of the planned 228 in Part A at the time of abstract submission.
    Clinical • P2 data
    |
    BRAF (B-raf proto-oncogene) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    BRAF mutation • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF L597
    |
    ulixertinib (BVD-523)